Aktis Oncology, Inc. · NASDAQ:AKTS
Aktis Oncology — TD Cowen 46th Annual Healthcare Conference (March 2026)
12 slides from Aktis Oncology's conference presentation, March 2026
Slide 1: Maximizing the Impact of Radiopharmaceuticals
Maximizing the Impact of Radiopharmaceuticals TD Cowen 46th Annual Healthcare Conference March 2026 1
Slide 2: Disclaimer
Disclaimer Information in this presentation and the accompanying oral presentation contains forward-looking statements within the meaning of the Private Securities Litigation Act of 1995 that involve substantial risks and uncertainties about Aktis Oncology and the industry in which Aktis Oncology op
Slide 3: Aktis investment highlights
Aktis investment highlights • Radiopharmaceutical field is ripening and has big category potential Several anticipated catalysts • Miniprotein radioconjugate platform is designed over next 12-24 months to open white-space opportunities • Two clinical proof-of-concepts • Advancement of 2 additional •
Slide 4: Aktis seeks to significantly expand the addressable patient population for radiopharmaceuticals
Aktis seeks to significantly expand the addressable patient population for radiopharmaceuticals TOTAL INCIDENCE, METASTATIC SOLID TUMORS RADIOPHARMACEUTICAL TARGETS TODAY Bladder 1% 1% Sarcoma PSMA SSTR2 Melanoma Brain* <1% Liver Esopheageal 3% 2% 3% Up to Up to Stomach 3% 24K 38K Ovarian 4% address
Slide 5: Miniproteins are designed to address a broad target universe
Miniproteins are designed to address a broad target universe MINIPROTEINS PRIORITIZED FOR RADIOCONJUGATES TRANSFORMATIONAL POTENTIAL ✔ Increase addressable tumor types Isotope-agnostic to ✔ Enable use in earlier lines of therapy image and treat ✔ Broaden prescriber base to oncology Non-cleavable lin
Slide 6: Aktis is advancing a novel pipeline for large patient populations
Aktis is advancing a novel pipeline for large patient populations PROGRAM TARGET/INDICATION DISCOVERY IND-ENABLING PHASE 1b PHASE 2/3 UPCOMING MILESTONES Nectin-4 expressing AKY-1189 Preliminary data 1Q’27 solid tumors Imaging/ dosimetry data mid’26 B7-H3 expressing AKY-2519 IND filing 1H’26 solid t
Slide 7: Total addressable market for radiopharmaceuticals is projected to reach $25-60+ billion post-2030
Total addressable market for radiopharmaceuticals is projected to reach $25-60+ billion post-2030 Total addressable market projections for radiopharmaceuticals Radiopharmaceuticals Note: ~$35B in 2030 for ADCs projected to mirror ~25-35+ growth of ADC market TAM ($B) Keys to unlocking the ~6-9 2 pot
Slide 8: Multi-indication, multi-tumor opportunities for AKY-1189 and AKY-2519
Multi-indication, multi-tumor opportunities for AKY-1189 and AKY-2519 Initial addressable patient populations Forecasted worldwide peak sales4 Metastatic Nectin-4 B7-H3 Initial Indication incidence expression expression in US1 Positioning positive2 positive3 $5.4 Billion Locally advanced ~4.2k 2L 86
Slide 9: Established capabilities at each node of end-to-end supply chain
Established capabilities at each node of end-to-end supply chain Radiopharmaceutical Development Isotope Production Fully operational facility capable of Multiple US/EU 225Ac all development stages suppliers with priority access Experience with majority of Generator and accelerator therapeutic and i
Slide 10: Accomplished leadership team & premier scientific advisors
Accomplished leadership team & premier scientific advisors Senior leadership team played leading roles in 14 FDA product approvals Matthew Roden, PhD Tyler Benedum, PhD Akos Czibere, MD PhD Paul Feldman, PhD Kyle Kuvalanka, MBA Shulamit Ron-Bigger, PhD President & CEO Chief Technical Officer Chief M
Slide 11: Fully integrated: Platform, pipeline, supply chain, and more
Fully integrated: Platform, pipeline, supply chain, and more Novel and Differentiated Platform Lead Programs Accomplished Addressing Large Market Leadership Team Tumor Types Strong Imaging Proof-of- Balance Sheet Concept in Patients Premier Pipeline Investor Syndicate Pillars of value of Programs Is
Slide 12: Thank You
Thank You — =
Aktis Oncology — TD Cowen 46th Annual Healthcare Conference (March 2026) on 6ix